Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 10 | 2025 | 144 | 4.990 |
Why?
|
| Mohs Surgery | 10 | 2025 | 28 | 3.590 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2021 | 163 | 1.980 |
Why?
|
| Transplant Recipients | 2 | 2021 | 12 | 1.370 |
Why?
|
| Melanoma | 2 | 2023 | 141 | 1.280 |
Why?
|
| Postoperative Complications | 3 | 2021 | 611 | 1.150 |
Why?
|
| Patient Satisfaction | 2 | 2025 | 96 | 1.080 |
Why?
|
| Quality of Life | 2 | 2025 | 487 | 1.010 |
Why?
|
| Patients | 2 | 2017 | 17 | 0.940 |
Why?
|
| Patient Education as Topic | 1 | 2025 | 91 | 0.910 |
Why?
|
| Skin Abnormalities | 2 | 2021 | 5 | 0.900 |
Why?
|
| Organ Transplantation | 2 | 2021 | 13 | 0.870 |
Why?
|
| Anxiety | 1 | 2025 | 149 | 0.870 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2023 | 3 | 0.830 |
Why?
|
| Erythema | 1 | 2021 | 4 | 0.750 |
Why?
|
| Parotid Diseases | 1 | 2021 | 1 | 0.730 |
Why?
|
| Cheek | 1 | 2021 | 9 | 0.730 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 163 | 0.720 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2021 | 9 | 0.720 |
Why?
|
| Fistula | 1 | 2021 | 17 | 0.710 |
Why?
|
| Family Practice | 1 | 2021 | 45 | 0.700 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 27 | 0.690 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 63 | 0.680 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 148 | 0.660 |
Why?
|
| Cicatrix | 2 | 2022 | 14 | 0.590 |
Why?
|
| Humans | 23 | 2025 | 28095 | 0.570 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 346 | 0.570 |
Why?
|
| Face | 1 | 2017 | 26 | 0.540 |
Why?
|
| Immunomodulation | 1 | 2016 | 20 | 0.530 |
Why?
|
| Skin Diseases | 1 | 2016 | 29 | 0.530 |
Why?
|
| Physicians | 1 | 2017 | 83 | 0.510 |
Why?
|
| Neoplasms | 2 | 2016 | 808 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 329 | 0.470 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 10 | 0.470 |
Why?
|
| Societies, Medical | 1 | 2015 | 93 | 0.450 |
Why?
|
| Symptom Assessment | 1 | 2012 | 15 | 0.400 |
Why?
|
| Physician's Role | 1 | 2012 | 29 | 0.390 |
Why?
|
| Referral and Consultation | 1 | 2012 | 97 | 0.370 |
Why?
|
| Palliative Care | 1 | 2012 | 82 | 0.370 |
Why?
|
| Communication | 2 | 2025 | 178 | 0.360 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 679 | 0.350 |
Why?
|
| Decision Making | 1 | 2012 | 175 | 0.350 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 971 | 0.340 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 478 | 0.340 |
Why?
|
| Dermatology | 2 | 2020 | 15 | 0.340 |
Why?
|
| Treatment Outcome | 5 | 2021 | 2378 | 0.250 |
Why?
|
| Male | 8 | 2021 | 13490 | 0.240 |
Why?
|
| Risk Factors | 2 | 2021 | 2081 | 0.230 |
Why?
|
| Physician-Patient Relations | 1 | 2025 | 115 | 0.220 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2022 | 72 | 0.220 |
Why?
|
| Skin | 2 | 2021 | 149 | 0.200 |
Why?
|
| Surgical Flaps | 2 | 2022 | 23 | 0.200 |
Why?
|
| Female | 10 | 2020 | 15155 | 0.200 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 6 | 0.190 |
Why?
|
| Torso | 3 | 2018 | 5 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 243 | 0.190 |
Why?
|
| Ulcer | 1 | 2021 | 5 | 0.190 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2021 | 10 | 0.180 |
Why?
|
| Neuromuscular Agents | 1 | 2021 | 5 | 0.180 |
Why?
|
| Cardiologists | 1 | 2020 | 3 | 0.180 |
Why?
|
| Expert Testimony | 1 | 2020 | 7 | 0.180 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 12 | 0.170 |
Why?
|
| Epinephrine | 1 | 2020 | 37 | 0.170 |
Why?
|
| Surgeons | 1 | 2020 | 50 | 0.170 |
Why?
|
| Recurrence | 1 | 2020 | 322 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 46 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 67 | 0.160 |
Why?
|
| Thumb | 1 | 2019 | 9 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 62 | 0.160 |
Why?
|
| Molluscum Contagiosum | 1 | 2018 | 2 | 0.160 |
Why?
|
| Lasers, Dye | 1 | 2018 | 2 | 0.160 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 8 | 0.150 |
Why?
|
| Time Factors | 2 | 2020 | 1591 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 15 | 0.150 |
Why?
|
| Radiodermatitis | 1 | 2018 | 1 | 0.150 |
Why?
|
| Risk Assessment | 1 | 2021 | 612 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 113 | 0.150 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 44 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 44 | 0.150 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 113 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2018 | 48 | 0.140 |
Why?
|
| Acyclovir | 1 | 2017 | 8 | 0.140 |
Why?
|
| Middle Aged | 5 | 2018 | 7138 | 0.140 |
Why?
|
| Herpesvirus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2017 | 10 | 0.140 |
Why?
|
| Herpes Zoster | 1 | 2017 | 20 | 0.140 |
Why?
|
| Esthetics | 1 | 2017 | 5 | 0.140 |
Why?
|
| Observer Variation | 1 | 2017 | 43 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 164 | 0.140 |
Why?
|
| Visual Perception | 1 | 2017 | 45 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 183 | 0.130 |
Why?
|
| HIV Infections | 1 | 2018 | 159 | 0.130 |
Why?
|
| Lichen Planus | 1 | 2015 | 2 | 0.130 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 2021 | 0.120 |
Why?
|
| Chlorhexidine | 1 | 2015 | 7 | 0.120 |
Why?
|
| Povidone-Iodine | 1 | 2015 | 8 | 0.120 |
Why?
|
| Neck | 1 | 2015 | 26 | 0.120 |
Why?
|
| Eye | 1 | 2015 | 36 | 0.120 |
Why?
|
| Extremities | 1 | 2015 | 22 | 0.120 |
Why?
|
| Health Care Surveys | 1 | 2015 | 67 | 0.120 |
Why?
|
| Aged | 4 | 2020 | 5400 | 0.100 |
Why?
|
| Arkansas | 1 | 2012 | 15 | 0.100 |
Why?
|
| Marital Status | 1 | 2012 | 16 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2012 | 26 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2012 | 28 | 0.100 |
Why?
|
| Religion | 1 | 2012 | 25 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 50 | 0.100 |
Why?
|
| Employment | 1 | 2012 | 49 | 0.100 |
Why?
|
| Educational Status | 1 | 2012 | 112 | 0.100 |
Why?
|
| Longevity | 1 | 2012 | 134 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2022 | 2546 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2012 | 1248 | 0.080 |
Why?
|
| United States | 1 | 2015 | 2146 | 0.080 |
Why?
|
| Animals | 1 | 2016 | 10418 | 0.050 |
Why?
|
| Adult | 1 | 2015 | 7740 | 0.050 |
Why?
|
| Nose | 1 | 2022 | 23 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 12 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 60 | 0.050 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2019 | 9 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2019 | 15 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 16 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 28 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 47 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 562 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2017 | 2 | 0.040 |
Why?
|
| Virus Activation | 1 | 2017 | 9 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2018 | 271 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2017 | 112 | 0.030 |
Why?
|
| Oklahoma | 1 | 2020 | 1007 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2015 | 45 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 258 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 120 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 3122 | 0.020 |
Why?
|
| Child | 1 | 2017 | 2242 | 0.020 |
Why?
|